In a filing, Catalyst Pharmaceuticals Inc revealed its Chief Strategy Officer Sundaram Preethi unloaded Company’s shares for reported $61377.0 on Jun 10 ’25. In the deal valued at $26.41 per share,2,324 shares were sold. As a result of this transaction, Sundaram Preethi now holds 42,681 shares worth roughly $0.93 million.
Then, Sundaram Preethi sold 1,600 shares, generating $42,272 in total proceeds. Upon selling the shares at $26.42, the Chief Strategy Officer now owns 41,081 shares.
Before that, Sundaram Preethi bought 1,600 shares. Catalyst Pharmaceuticals Inc shares valued at $42,268 were divested by the Officer at a price of $26.42 per share.
Robert W. Baird initiated its Catalyst Pharmaceuticals Inc [CPRX] rating to an Outperform in a research note published on February 04, 2025; the price target was $28. A number of analysts have revised their coverage, including Stephens’s analysts, who began to cover the stock in mid November with a ‘”an Overweight”‘ rating. Citigroup began covering CPRX with “Buy” recommendation on March 14, 2024. BofA Securities started covering the stock on March 07, 2024. It rated CPRX as “a Buy”.
Price Performance Review of CPRX
On Monday, Catalyst Pharmaceuticals Inc [NASDAQ:CPRX] saw its stock jump 2.89% to $21.73. Over the last five days, the stock has gained 4.47%. Catalyst Pharmaceuticals Inc shares have risen nearly 26.04% since the year began. Nevertheless, the stocks have risen 4.12% over the past one year.
How much short interest is there in Catalyst Pharmaceuticals Inc?
A steep rise in short interest was recorded in Catalyst Pharmaceuticals Inc stocks on 2025-07-15, growing by 1.19 million shares to a total of 8.92 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 7.73 million shares. There was a rise of 13.32%, which implies that there is a positive sentiment for the stock.
